Recombinant Human EREG Protein，His

EREG (Epiregulin) is a member of the epidermal growth factor (EGF) family and plays a crucial role in various biological processes, including cell proliferation, differentiation, and tissue repair. Initially identified for its involvement in skin and epithelial tissues, EREG has gained attention for its implications in cancer biology, particularly in promoting tumor growth and metastasis. Research indicates that EREG is often overexpressed in several types of cancer, such as colorectal, breast, and lung cancers, making it a potential biomarker for cancer diagnosis and prognosis. Additionally, EREG functions by binding to the epidermal growth factor receptor (EGFR), triggering signaling pathways that contribute to cellular growth and survival. Given its dual role in physiological processes and pathological conditions, EREG is a target of interest for therapeutic interventions. Studies focusing on the recombinant expression of EREG are critical for elucidating its functional mechanisms and interactions, enabling the development of EREG-targeted therapies. Current research aims to provide insights into the structural and functional attributes of EREG, exploring its potential in personalized medicine and novel cancer treatments. Understanding the biochemistry of EREG at the molecular level will facilitate the discovery of inhibitors that could mitigate its oncogenic effects, thereby contributing to more effective cancer therapies.